←
Matias Serebrinsky628 posts
Matias Serebrinsky avatar

Matias Serebrinsky

@matisere

Investor in neuro @psymedventures. Co-host businesstrip.fm. Figuring it all out.

◷ Joined June 2010▧ 40 Photos and videos
Mary Ann Azevedo avatar
⟳ Matias Serebrinsky retweeted
Mary Ann Azevedo@bayareawriter·Nov 10

What happens between mental health appointments can be as important as what happens during them. That’s the gap @SiggyMD is targeting. The startup raised $6 million in pre-seed funding led by @VillageGlobal, I reported exclusively for @crunchbasenews. Its founders have built healthcare companies before: @SabbaghJonathan co-founded Journey Clinical, while @edvardenge co-founded Nurx. With Siggy, patients start with an AI conversation about their history before meeting a licensed clinician. Daily check-ins track mood, sleep and medication side effects. Patients can also connect wearables such as Oura, Whoop or Apple Watch. That information feeds into a daily “Siggy Score” visible to both patient and clinician, with changes flagged for clinical review. Clinicians make diagnoses, prescribe medication and decide how to adjust treatment. A few other details stood out: • Siggy accepts commercial insurance in all 50 states. • The founders say the service will be permanently free to veterans. • Patients can keep seeing their existing therapists. • Several investors had previously backed one or both founders, including Albert Wenger and Immad Akhund. More on the founders’ plans and why they teamed up in the link in the comments:

Post attachmentPost attachment
Matias Serebrinsky avatar
Matias Serebrinsky@matisere·Nov 9

We @PsymedVentures first backed Delix Therapeutics in 2021 and have invested in every round since. Proud to be in again for the Series C. It's been inspiring to see the team figure things out and execute. Neuroplastogens without the trip is still one of the biggest bets in neuro.

Delix Closes $100M Series C Led by Johnson & Johnson This morning, neuroplastogen drug developer Delix Therapeutics announced the closing of a $100 million Series C financing. As we reported in August, Johnson & Johnson’s led the round, via its venture arm. Delix plans to initiate a trial of its lead candidate, zalsupindole, in H127.

Post attachment
Matias Serebrinsky avatar
Matias Serebrinsky@matisere·Nov 5

A gene therapy you can turn on and off with a low-dose pill. Science is cool! We had Brian on the podcast back in 2023 businesstrip.fm/1173518/epis…

Dreadds work in humans nejm.org/doi/full/10.1056/NE…

Jonathan Sabbagh avatar
⟳ Matias Serebrinsky retweeted
Jonathan Sabbagh@SabbaghJonathan·Nov 5

Meet @SiggyMD! 🚀 @edvardenge and I are launching with $6M led by @VillageGlobal to make expert mental healthcare part of everyday life. AI + licensed clinicians for the weeks between appointments. Our story in @CrunchbaseNews: news.crunchbase.com/venture/…

Crunchbase News avatar
⟳ Matias Serebrinsky retweeted
Crunchbase News@crunchbasenews·Nov 5

Siggy has raised $6 million in pre-seed funding to build a mental health service that uses AI to collect patients’ histories and track progress between appointments with licensed clinicians, the startup told Crunchbase News exclusively. news.crunchbase.com/venture/…

Shahin Farshchi avatar
⟳ Matias Serebrinsky retweeted
Shahin Farshchi@Farshchi·Nov 3

Our eyes, ears, taste, touch, and smell have served as incredible neural interfaces, allowing to humanity to interact with subatomic particles to distant galaxies. Sure, reading directly from neurons would be great, but I'm optimistic that we can build some amazing BCI by getting creative with our existing senses:

Shahin Farshchi at Lux Capital likes to say neural interfaces have been "5 years away" for 20 years. So what's changed? He joins us on Business Trip to discuss opportunities in neuro. We get into his BCI investing framework, voice as an interface, and how he spots the next tech wave early. businesstrip.fm/1173518/epis… @Farshchi @Lux_Capital

Greg Kubin avatar
⟳ Matias Serebrinsky retweeted
Greg Kubin@kubeans·Nov 2

Shahin Farshchi at Lux Capital likes to say neural interfaces have been "5 years away" for 20 years. So what's changed? He joins us on Business Trip to discuss opportunities in neuro. We get into his BCI investing framework, voice as an interface, and how he spots the next tech wave early. businesstrip.fm/1173518/epis… @Farshchi @Lux_Capital

Matias Serebrinsky avatar
Matias Serebrinsky@matisere·Oct 29

cool way of helping us understand how fast things will feel moving forward

Time is becoming a poor measure of how distant the future really is. Ten years used to be a manageable stretch of the future, but with AI, it does not tell you much anymore. After much thinking, I came up with a better framing to measure the future: tokens of thinking. Let me explain:

Matias Serebrinsky avatar
Matias Serebrinsky@matisere·Oct 22

Been using Gigi for a few weeks and it really is as good as this vid makes it look

Your AI agent can find anyone on the internet. It has no idea who can actually get you to them. Until now. Meet Gigi: the trusted network that gives agents access to people. That investor you've been dying to meet. The engineer you'd hire tomorrow. The dream customer you can't get in front of. Chances are, someone in your extended network knows them. Gigi finds out who. Your agent can now search your network, ask the agents of people you trust to search theirs, and find real warm paths to the people you want to reach. All without exposing anyone's contacts. And without reading a single email or message. Your network is no longer who you know. It's who your agent can get you to. Think of one person you wish you knew. Ask Gigi to find your way in. Link in the comments👇

3:24
Clara Gold avatar
⟳ Matias Serebrinsky retweeted
Clara Gold@Clara_Gold·Oct 22

Your AI agent can find anyone on the internet. It has no idea who can actually get you to them. Until now. Meet Gigi: the trusted network that gives agents access to people. That investor you've been dying to meet. The engineer you'd hire tomorrow. The dream customer you can't get in front of. Chances are, someone in your extended network knows them. Gigi finds out who. Your agent can now search your network, ask the agents of people you trust to search theirs, and find real warm paths to the people you want to reach. All without exposing anyone's contacts. And without reading a single email or message. Your network is no longer who you know. It's who your agent can get you to. Think of one person you wish you knew. Ask Gigi to find your way in. Link in the comments👇

3:24
Matias Serebrinsky avatar
Matias Serebrinsky@matisere·Oct 13

having said that - i remain less convinced that non-invasive is the obvious unlock to scaling. could be and maybe super noisy data just works, but im not convinced. my take is that we'll have a bunch of different levels of invasiveness and each will be super helpful and huge in different ways

Matias Serebrinsky avatar
Matias Serebrinsky@matisere·Oct 12

great post by @satpugnet! put perfect words to what a few of us have been feeling for a while. when I started @PsymedVentures, I would mostly ask "what can AI do for neuro?" now the opposite question is equally interesting "what can neuro do for AI?"

The human brain is approaching its ChatGPT moment. I spent 6 months writing Phase Lock: a manifesto on how brain computer interfaces can help align AI and preserve human agency. If you only ever read one thing from me, read this.

Post attachmentPost attachment
Alex Masmej avatar
⟳ Matias Serebrinsky retweeted
Alex Masmej@AlexMasmej·Oct 8

AI will scale BCI, and BCI will scale AI I’ve never seen such a bullish piece on what @neurode_labs is building Thrilling time to be at the neurotech frontier

The human brain is approaching its ChatGPT moment. I spent 6 months writing Phase Lock: a manifesto on how brain computer interfaces can help align AI and preserve human agency. If you only ever read one thing from me, read this.

Post attachmentPost attachment
Powerhouse Biology avatar
⟳ Matias Serebrinsky retweeted
Powerhouse Biology@Powerhouse_Bio·Oct 9

Do we dare use the word superhuman, and at the same time stay true to science? Welcome to a new frontier of human biology: At Powerhouse Biology, we build capability therapeutics, medicines that add function to human cells. Stay tuned for October 12, when we share the 2026 White Paper "Engineered human resilience and durability".

1:46